1.199 Billion USD
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Seeking Alpha 03:15 24/11/2022
ImmunoGen: Elucidating Ramifications Of The Elahere Approval
ImmunoGen recently gained the accelerated approval of mirvetuxim...
Zacks Investment Research 14:18 15/11/2022
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
ImmunoGen (IMGN) receives accelerated FDA approval for its lead ...
Zacks Investment Research 15:48 07/11/2022
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
ImmunoGen (IMGN) reports a wider-than-expected loss in third-qua...
Seeking Alpha 13:22 04/11/2022
ImmunoGen, Inc. (IMGN) Q3 2022 Earnings Call Transcript
ImmunoGen, Inc. (NASDAQ:IMGN ) Q3 2022 Earnings Conference Call ...